Royalty Pharma plc Class A Ordinary Shares (RPRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Royalty Pharma plc Class A Ordinary Shares (RPRX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How RPRX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | 44% | 65.6% | $770.9M | $2.38B | 7% |
| FY 2024 | $2.26B | 44% | 57.1% | $859.0M | $2.67B | 6.4% |
| FY 2023 | $2.35B | 44% | 63.4% | $1.13B | $2.88B | 9.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RPRX)
- ✓Live walkthrough of RPRX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RPRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RPRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RPRX. Explore sector supply chains on /butterfly.
RPRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Royalty Pharma plc Class A Ordinary Shares (RPRX)?
In FY 2025 (10-K), RPRX converted $2.4B of revenue into a 44% gross margin, 44% operating margin, and $2.4B in free cash flow (100.2% FCF margin).